Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat observational study in patients with heart failure
ChiCTR2300077292Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vericiguat in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoints: Left ventricular ejection fraction and NT-proBNP. Started Aug 2023; status: recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2300077292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077292.